NVCR - These 3 European Biotechs Can Help Recession-Proof Your Portfolio
The biotech industry in Europe remains fragmented due to limited early stage capital and more risk-averse investor sentiment. While a small group of companies have successfully developed new products and financed adequate research and development, many other small ones struggle to get by with constrained capital resources.
Innovation knows no boundaries, and some of the most compelling investments hail from overseas -- including Europe. But here in the U.S., investors are treading carefully, fearing the start of another recession taking hold of the economy. To diversify from the U.S., investors should look at foreign companies in industries such as biotech where the patient demand for cutting-edge medicines exists regardless of the broader economic outlook.
Let's review some European biotechs worth considering for your portfolio. No need to get out your passport: These companies are also listed on the U.S. exchanges.